Hanning, SM;
Muhamed, J;
Orlu-Gul, M;
(2015)
Investigation into the dosage form attributes of currently UK licensed cardiovascular and Parkinson's disease drug products.
International Journal of Pharmaceutics
, 479
(1)
159 - 162.
10.1016/j.ijpharm.2014.12.065.
![[thumbnail of IJP_dosage form attributes_accepted version_2014.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
IJP_dosage form attributes_accepted version_2014.pdf Available under License : See the attached licence file. Download (400kB) |
Abstract
Globally, there is a continuous rise in the older population (over 65 years), particularly in developed countries. As many diseases are age-related, older adults represent a highly heterogeneous cohort. This presents a major challenge for both the pharmaceutical industry and healthcare professionals. The purpose of this research was to attract attention towards the appropriateness of geriatric formulations by investigating the dosage form attributes of currently UK licensed cardiovascular and Parkinson's disease drug products. Medication available in the UK for cardiovascular disorders and Parkinson's disease were screened and the available formulations, packaging and patient information leaflets of these medicines were analysed, with the goal of raising awareness of the need to cater for elderly patients with increasing difficulty in managing their medication. It emerged that although cardiovascular disorders and Parkinson's disease are more prevalent in older people, many treatment options have not been optimised for this cohort. In particular, older patient centred dosage forms, specific dosing requirements, excipients, patient-friendly packaging and easy-to-follow patient information were highlighted as areas to be considered in order to optimise health outcomes in the ageing population.
| Type: | Article |
|---|---|
| Title: | Investigation into the dosage form attributes of currently UK licensed cardiovascular and Parkinson's disease drug products |
| Location: | Netherlands |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ijpharm.2014.12.065 |
| Publisher version: | http://dx.doi.org/10.1016/j.ijpharm.2014.12.065 |
| Language: | English |
| Additional information: | NOTICE: this is the author’s version of a work that was accepted for publication in International Journal of Pharmaceutics. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in International Journal of Pharmaceutics, [479,1, 2/2015] http://dx.doi.org/10.1016/j.ijpharm.2014.12.065 |
| Keywords: | Cardiovascular disease, Dosage form, Excipient, Older people, Parkinson’s disease, Polypharmacy |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmaceutics |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1460764 |
Archive Staff Only
 |
View Item |
